SMOFKABIVEN ELECTROLYTE FREE amino acids 5.1% / lipids 3.8% / glucose 12.7% emulsion for intravenous infusion bag 986 mL Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

smofkabiven electrolyte free amino acids 5.1% / lipids 3.8% / glucose 12.7% emulsion for intravenous infusion bag 986 ml

fresenius kabi australia pty ltd - medium chain triglycerides, quantity: 60 g/l; fish oil - rich in omega-3 acids, quantity: 30 g/l; olive oil, quantity: 50 g/l; soya oil, quantity: 60 g/l - injection, intravenous infusion - excipient ingredients: dl-alpha-tocopherol; water for injections; sodium hydroxide; egg lecithin; glycerol; sodium oleate - parenteral nutrition for adult patients when oral or enteral nutrition is impossible, insufficient or contraindicated.

Cefepime Kabi Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

cefepime kabi

fresenius kabi new zealand limited - cefepime dihydrochloride monohydrate 1.1892 g equivalent to cefepime 1g - powder for injection - 1 g - active: cefepime dihydrochloride monohydrate 1.1892 g equivalent to cefepime 1g excipient: arginine - adults: cefepime kabi is indicated for the treatment of the indications listed below when caused by susceptible bacteria: · lower respiratory tract infections, including pneumonia and bronchitis · urinary tract infections , both complicated, including pyelonephritis, and uncomplicated infections · skin and skin structure infections · intra-abdominal infections, including peritonitis and biliary tract infections · septicaemia · empiric treatment in febrile neutropenic patients.

Cefepime Kabi Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

cefepime kabi

fresenius kabi new zealand limited - cefepime dihydrochloride monohydrate 2.3785 g equivalent to cefepime 2g - powder for injection - 2 g - active: cefepime dihydrochloride monohydrate 2.3785 g equivalent to cefepime 2g excipient: arginine - adults: cefepime kabi is indicated for the treatment of the indications listed below when caused by susceptible bacteria: · lower respiratory tract infections, including pneumonia and bronchitis · urinary tract infections , both complicated, including pyelonephritis, and uncomplicated infections · skin and skin structure infections · intra-abdominal infections, including peritonitis and biliary tract infections · septicaemia · empiric treatment in febrile neutropenic patients.

PicoPrep Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

picoprep

fresenius kabi new zealand limited - citric acid 771.868 mg/g; heavy magnesium oxide 225.128 mg/g; sodium picosulfate 0.64 mg/g;   - powder for oral solution - 0.64 mg/g - active: citric acid 771.868 mg/g heavy magnesium oxide 225.128 mg/g sodium picosulfate 0.64 mg/g   excipient: aspartame

Ceftazidime Kabi Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

ceftazidime kabi

fresenius kabi new zealand limited - ceftazidime pentahydrate 1.1648 g equivalent to ceftazidime 1 g (sterile);   - powder for injection - 1 g - active: ceftazidime pentahydrate 1.1648 g equivalent to ceftazidime 1 g (sterile)   excipient: sodium carbonate - indicated for the treatment of adults and children including neonates with single or multiple infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other beta-lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected. susceptibility to ceftazidime will vary with geography and time and local susceptibility data should be consulted where available (see section 5.1 pharmacodynamic properties). indications include: - severe infections e.g. - septicaemia, bacteraemia, peritonitis, meningitis. - infections in immunosuppressed patients. - infections in patients in intensive care, e.g. infected burns. - respiratory tract infections including lung infections in cystic fibrosis. - ear, nose and throat infections. - urinary tract infections. - skin and soft tissue infections. - gastrointestinal, biliary and abdominal infections. - bone and joint infections. - infections associated with haemo- and peritoneal dialysis and with continuous ambulatory peritoneal dialysis (capd).

Ceftazidime Kabi Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

ceftazidime kabi

fresenius kabi new zealand limited - ceftazidime pentahydrate 2.3296 g equivalent to ceftazidime 2 g (sterile);   - powder for injection - 2 g - active: ceftazidime pentahydrate 2.3296 g equivalent to ceftazidime 2 g (sterile)   excipient: sodium carbonate - indicated for the treatment of adults and children including neonates with single or multiple infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other beta-lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected. susceptibility to ceftazidime will vary with geography and time and local susceptibility data should be consulted where available (see section 5.1 pharmacodynamic properties). indications include: - severe infections e.g. - septicaemia, bacteraemia, peritonitis, meningitis. - infections in immunosuppressed patients. - infections in patients in intensive care, e.g. infected burns. - respiratory tract infections including lung infections in cystic fibrosis. - ear, nose and throat infections. - urinary tract infections. - skin and soft tissue infections. - gastrointestinal, biliary and abdominal infections. - bone and joint infections. - infections associated with haemo- and peritoneal dialysis and with continuous ambulatory peritoneal dialysis (capd).

Busulfan Fresenius Kabi Evropska unija - angleščina - EMA (European Medicines Agency)

busulfan fresenius kabi

fresenius kabi deutschland gmbh - busulfan - hematopoietic stem cell transplantation - alkyl sulfonates - busulfan fresenius kabi followed by cyclophosphamide (bucy2) is indicated as conditioning treatment prior to conventional haematopoietic progenitor cell transplantation (hpct) in adult patients when the combination is considered the best available option.busulfan fresenius kabi followed by cyclophosphamide (bucy4) or melphalan (bumel) is indicated as conditioning treatment prior to conventional haematopoietic progenitor cell transplantation in paediatric patients.

SMOFKABIVEN amino acids 5.1% / lipids 3.8% / glucose 12.7% / electrolytes 0.7% emulsion for intravenous infusion bag 2463 mL Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

smofkabiven amino acids 5.1% / lipids 3.8% / glucose 12.7% / electrolytes 0.7% emulsion for intravenous infusion bag 2463 ml

fresenius kabi australia pty ltd - medium chain triglycerides, quantity: 60 g/l; fish oil - rich in omega-3 acids, quantity: 30 g/l; olive oil, quantity: 50 g/l; soya oil, quantity: 60 g/l - injection, intravenous infusion - excipient ingredients: sodium oleate; dl-alpha-tocopherol; glycerol; egg lecithin; water for injections; sodium hydroxide - parenteral nutrition for adult patients and paediatric patients aged 2 years and above when oral or enteral nutrition is impossible, insufficient or contraindicated.

SMOFKABIVEN amino acids 5.1% / lipids 3.8% / glucose 12.7% / electrolytes 0.7% emulsion for intravenous infusion bag 1970 mL Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

smofkabiven amino acids 5.1% / lipids 3.8% / glucose 12.7% / electrolytes 0.7% emulsion for intravenous infusion bag 1970 ml

fresenius kabi australia pty ltd - fish oil - rich in omega-3 acids, quantity: 30 g/l; soya oil, quantity: 60 g/l; olive oil, quantity: 50 g/l; medium chain triglycerides, quantity: 60 g/l - injection, intravenous infusion - excipient ingredients: sodium hydroxide; sodium oleate; egg lecithin; glycerol; water for injections; dl-alpha-tocopherol - parenteral nutrition for adult patients and paediatric patients aged 2 years and above when oral or enteral nutrition is impossible, insufficient or contraindicated.

SMOFKABIVEN amino acids 5.1% / lipids 3.8% / glucose 12.7% / electrolytes 0.7% emulsion for intravenous infusion bag 1477 mL Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

smofkabiven amino acids 5.1% / lipids 3.8% / glucose 12.7% / electrolytes 0.7% emulsion for intravenous infusion bag 1477 ml

fresenius kabi australia pty ltd - olive oil, quantity: 50 g/l; fish oil - rich in omega-3 acids, quantity: 30 g/l; medium chain triglycerides, quantity: 60 g/l; soya oil, quantity: 60 g/l - injection, intravenous infusion - excipient ingredients: water for injections; dl-alpha-tocopherol; sodium oleate; sodium hydroxide; egg lecithin; glycerol - parenteral nutrition for adult patients and paediatric patients aged 2 years and above when oral or enteral nutrition is impossible, insufficient or contraindicated.